These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19053783)

  • 21. Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors.
    Han Y; Giroux A; Grimm EL; Aspiotis R; Francoeur S; Bayly CI; Mckay DJ; Roy S; Xanthoudakis S; Vaillancourt JP; Rasper DM; Tam J; Tawa P; Thornberry NA; Paterson EP; Garcia-Calvo M; Becker JW; Rotonda J; Nicholson DW; Zamboni RJ
    Bioorg Med Chem Lett; 2004 Feb; 14(3):805-8. PubMed ID: 14741294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead.
    Yin Z; Patel SJ; Wang WL; Wang G; Chan WL; Rao KR; Alam J; Jeyaraj DA; Ngew X; Patel V; Beer D; Lim SP; Vasudevan SG; Keller TH
    Bioorg Med Chem Lett; 2006 Jan; 16(1):36-9. PubMed ID: 16246553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytosolic and calcium-independent phospholipase A(2) mediate glioma-enhanced proangiogenic activity of brain endothelial cells.
    Giurdanella G; Motta C; Muriana S; Arena V; Anfuso CD; Lupo G; Alberghina M
    Microvasc Res; 2011 Jan; 81(1):1-17. PubMed ID: 21094175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors.
    Mermerian AH; Case A; Stein RL; Cuny GD
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3729-32. PubMed ID: 17449248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents.
    Jones P; Steinkühler C
    Curr Pharm Des; 2008; 14(6):545-61. PubMed ID: 18336299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonpeptidic inhibitors of human neutrophil elastase. 7. Design, synthesis, and in vitro activity of a series of pyridopyrimidine trifluoromethyl ketones.
    Edwards PD; Andisik DW; Strimpler AM; Gomes B; Tuthill PA
    J Med Chem; 1996 Mar; 39(5):1112-24. PubMed ID: 8676347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The application of rational design on phospholipase A(2) inhibitors.
    Mouchlis VD; Barbayianni E; Mavromoustakos TM; Kokotos G
    Curr Med Chem; 2011; 18(17):2566-82. PubMed ID: 21568891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.
    Kalyvas A; Baskakis C; Magrioti V; Constantinou-Kokotou V; Stephens D; López-Vales R; Lu JQ; Yong VW; Dennis EA; Kokotos G; David S
    Brain; 2009 May; 132(Pt 5):1221-35. PubMed ID: 19218359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
    Bérubé M; Poirier D
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton.
    Connolly S; Bennion C; Botterell S; Croshaw PJ; Hallam C; Hardy K; Hartopp P; Jackson CG; King SJ; Lawrence L; Mete A; Murray D; Robinson DH; Smith GM; Stein L; Walters I; Wells E; Withnall WJ
    J Med Chem; 2002 Mar; 45(6):1348-62. PubMed ID: 11882004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substrate-Specific Inhibition Constants for Phospholipase A
    Mouchlis VD; Armando A; Dennis EA
    J Med Chem; 2019 Feb; 62(4):1999-2007. PubMed ID: 30615445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoroketone inhibition of Ca(2+)-independent phospholipase A2 through binding pocket association defined by hydrogen/deuterium exchange and molecular dynamics.
    Hsu YH; Bucher D; Cao J; Li S; Yang SW; Kokotos G; Woods VL; McCammon JA; Dennis EA
    J Am Chem Soc; 2013 Jan; 135(4):1330-7. PubMed ID: 23256506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pardaxin stimulation of phospholipases A2 and their involvement in exocytosis in PC-12 cells.
    Bloch-Shilderman E; Abu-Raya S; Trembovler V; Boschwitz H; Gruzman A; Linial M; Lazarovici P
    J Pharmacol Exp Ther; 2002 Jun; 301(3):953-62. PubMed ID: 12023524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoro ketone inhibitors of hydrolytic enzymes.
    Gelb MH; Svaren JP; Abeles RH
    Biochemistry; 1985 Apr; 24(8):1813-7. PubMed ID: 2990541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies of insulin secretory responses and of arachidonic acid incorporation into phospholipids of stably transfected insulinoma cells that overexpress group VIA phospholipase A2 (iPLA2beta ) indicate a signaling rather than a housekeeping role for iPLA2beta.
    Ma Z; Ramanadham S; Wohltmann M; Bohrer A; Hsu FF; Turk J
    J Biol Chem; 2001 Apr; 276(16):13198-208. PubMed ID: 11278673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes.
    Antonopoulou G; Barbayianni E; Magrioti V; Cotton N; Stephens D; Constantinou-Kokotou V; Dennis EA; Kokotos G
    Bioorg Med Chem; 2008 Dec; 16(24):10257-69. PubMed ID: 18993078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of specific peptide inhibitors for group I phospholipase A2: structure of a complex formed between phospholipase A2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 A resolution reveals unique features.
    Singh RK; Vikram P; Makker J; Jabeen T; Sharma S; Dey S; Kaur P; Srinivasan A; Singh TP
    Biochemistry; 2003 Oct; 42(40):11701-6. PubMed ID: 14529280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.
    Magrioti V; Kokotos G
    Expert Opin Ther Pat; 2010 Jan; 20(1):1-18. PubMed ID: 20021282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational Exploration of Natural Compounds to Target Cytosolic Phospholipase A 2 Protein: A Novel Therapeutic Target for Spinal Cord Injury.
    Fan H; Wang S; Zhao Q; Qin Z
    Curr Comput Aided Drug Des; 2018; 14(2):117-124. PubMed ID: 29359676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.